These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 28716427)

  • 41. Case-control study of the parkin gene in early-onset Parkinson disease.
    Clark LN; Afridi S; Karlins E; Wang Y; Mejia-Santana H; Harris J; Louis ED; Cote LJ; Andrews H; Fahn S; Waters C; Ford B; Frucht S; Ottman R; Marder K
    Arch Neurol; 2006 Apr; 63(4):548-52. PubMed ID: 16606767
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Influence of white matter MRI hyper-intensities on acute l-dopa response in patients with Parkinson's disease.
    Arena JE; Cerquetti D; Rossi M; Chaves H; Rollan C; Dossi DE; Merello M
    Parkinsonism Relat Disord; 2016 Mar; 24():126-8. PubMed ID: 26823237
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Juvenile-onset parkinsonism with digenic parkin and PINK1 mutations treated with subthalamic nucleus stimulation at 45 years after disease onset.
    Nakahara K; Ueda M; Yamada K; Koide T; Yoshimochi G; Funayama M; Kim JH; Yamakawa S; Mori A; Misumi Y; Uyama E; Hattori N; Ando Y
    J Neurol Sci; 2014 Oct; 345(1-2):276-7. PubMed ID: 25106695
    [No Abstract]   [Full Text] [Related]  

  • 44. Disease Progression in Patients with Parkin-Related Parkinson's Disease in a Longitudinal Cohort.
    Sun YM; Yu HL; Zhou XY; Xiong WX; Luo SS; Chen C; Liu FT; Zhao J; Tang YL; Liang XN; Yang YJ; Shen B; Shen Y; Yu WB; Ding ZT; An Y; Wu JJ; Wang J
    Mov Disord; 2021 Feb; 36(2):442-448. PubMed ID: 33107659
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The relationship between obsessive-compulsive symptoms and PARKIN genotype: The CORE-PD study.
    Sharp ME; Caccappolo E; Mejia-Santana H; Tang MX; Rosado L; Orbe Reilly M; Ruiz D; Louis ED; Comella C; Nance M; Bressman S; Scott WK; Tanner C; Waters C; Fahn S; Cote L; Ford B; Rezak M; Novak K; Friedman JH; Pfeiffer R; Payami H; Molho E; Factor SA; Nutt J; Serrano C; Arroyo M; Pauciulo MW; Nichols WC; Clark LN; Alcalay RN; Marder KS
    Mov Disord; 2015 Feb; 30(2):278-83. PubMed ID: 25393808
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Eye movement disorders are different in Parkin-linked and idiopathic early-onset PD.
    Machner B; Klein C; Sprenger A; Baumbach P; Pramstaller PP; Helmchen C; Heide W
    Neurology; 2010 Jul; 75(2):125-8. PubMed ID: 20625164
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Lewy body Parkinson's disease in a large pedigree with 77 Parkin mutation carriers.
    Pramstaller PP; Schlossmacher MG; Jacques TS; Scaravilli F; Eskelson C; Pepivani I; Hedrich K; Adel S; Gonzales-McNeal M; Hilker R; Kramer PL; Klein C
    Ann Neurol; 2005 Sep; 58(3):411-22. PubMed ID: 16130111
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A multidisciplinary study of patients with early-onset PD with and without parkin mutations.
    Lohmann E; Thobois S; Lesage S; Broussolle E; du Montcel ST; Ribeiro MJ; Remy P; Pelissolo A; Dubois B; Mallet L; Pollak P; Agid Y; Brice A;
    Neurology; 2009 Jan; 72(2):110-6. PubMed ID: 18987353
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A multitracer dopaminergic PET study of young-onset parkinsonian patients with and without parkin gene mutations.
    Ribeiro MJ; Thobois S; Lohmann E; du Montcel ST; Lesage S; Pelissolo A; Dubois B; Mallet L; Pollak P; Agid Y; Broussolle E; Brice A; Remy P;
    J Nucl Med; 2009 Aug; 50(8):1244-50. PubMed ID: 19617340
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Mutational analysis of the PINK1 gene in early-onset parkinsonism in Europe and North Africa.
    Ibáñez P; Lesage S; Lohmann E; Thobois S; De Michele G; Borg M; Agid Y; Dürr A; Brice A;
    Brain; 2006 Mar; 129(Pt 3):686-94. PubMed ID: 16401616
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Subclinical sensory abnormalities in unaffected PINK1 heterozygotes.
    Fiorio M; Valente EM; Gambarin M; Bentivoglio AR; Ialongo T; Albanese A; Barone P; Pellecchia MT; Brancati F; Moretto G; Fiaschi A; Tinazzi M
    J Neurol; 2008 Sep; 255(9):1372-7. PubMed ID: 18584234
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of endogenous mutant and wild-type PINK1 on Parkin in fibroblasts from Parkinson disease patients.
    Rakovic A; Grünewald A; Seibler P; Ramirez A; Kock N; Orolicki S; Lohmann K; Klein C
    Hum Mol Genet; 2010 Aug; 19(16):3124-37. PubMed ID: 20508036
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Exhaustive analysis of BH4 and dopamine biosynthesis genes in patients with Dopa-responsive dystonia.
    Clot F; Grabli D; Cazeneuve C; Roze E; Castelnau P; Chabrol B; Landrieu P; Nguyen K; Ponsot G; Abada M; Doummar D; Damier P; Gil R; Thobois S; Ward AJ; Hutchinson M; Toutain A; Picard F; Camuzat A; Fedirko E; Sân C; Bouteiller D; LeGuern E; Durr A; Vidailhet M; Brice A;
    Brain; 2009 Jul; 132(Pt 7):1753-63. PubMed ID: 19491146
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Mutation analysis of the PINK1 gene in 391 patients with Parkinson disease.
    Kumazawa R; Tomiyama H; Li Y; Imamichi Y; Funayama M; Yoshino H; Yokochi F; Fukusako T; Takehisa Y; Kashihara K; Kondo T; Elibol B; Bostantjopoulou S; Toda T; Takahashi H; Yoshii F; Mizuno Y; Hattori N
    Arch Neurol; 2008 Jun; 65(6):802-8. PubMed ID: 18541801
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Heterozygous PINK1 mutations: a susceptibility factor for Parkinson disease?
    Djarmati A; Hedrich K; Svetel M; Lohnau T; Schwinger E; Romac S; Pramstaller PP; Kostić V; Klein C
    Mov Disord; 2006 Sep; 21(9):1526-30. PubMed ID: 16755580
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy and safety of piribedil in early combination with L-dopa in the treatment of Parkinson's disease: a 6-month open study.
    Suwantamee J; Nidhinandana S; Srisuwananukorn S; Laptikultham S; Pisarnpong A; Chankrachang S; Bundhukul A
    J Med Assoc Thai; 2004 Nov; 87(11):1293-300. PubMed ID: 15825702
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Nicotine increases lifespan and rescues olfactory and motor deficits in a Drosophila model of Parkinson's disease.
    Chambers RP; Call GB; Meyer D; Smith J; Techau JA; Pearman K; Buhlman LM
    Behav Brain Res; 2013 Sep; 253():95-102. PubMed ID: 23871228
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Subthalamic nucleus stimulation modulates motor cortex oscillatory activity in Parkinson's disease.
    Devos D; Labyt E; Derambure P; Bourriez JL; Cassim F; Reyns N; Blond S; Guieu JD; Destée A; Defebvre L
    Brain; 2004 Feb; 127(Pt 2):408-19. PubMed ID: 14691060
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Parkin stabilizes PINK1 through direct interaction.
    Shiba K; Arai T; Sato S; Kubo S; Ohba Y; Mizuno Y; Hattori N
    Biochem Biophys Res Commun; 2009 Jun; 383(3):331-5. PubMed ID: 19358826
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A heterozygous effect for PINK1 mutations in Parkinson's disease?
    Abou-Sleiman PM; Muqit MM; McDonald NQ; Yang YX; Gandhi S; Healy DG; Harvey K; Harvey RJ; Deas E; Bhatia K; Quinn N; Lees A; Latchman DS; Wood NW
    Ann Neurol; 2006 Oct; 60(4):414-9. PubMed ID: 16969854
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.